RepliCel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates Apr 9, 2016
RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement Apr 7, 2016
RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection Mar 9, 2016
RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 mg and Submission to FDA of IBS-D Phase II Study Protocol Feb 12, 2016
RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent Covering RHB-104 Phase III Crohn’s Disease Program Feb 11, 2016
RedHill Biopharma Announces Collaboration with Germany’s Fraunhofer Institute for Oncology Drug RP101 Feb 9, 2016
Resverlogix’s Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal Jan 26, 2016
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin Dec 18, 2015
